Topic:

M&A

Latest Headlines

Latest Headlines

Report: Covidien buys New Wave Surgical for $100M+

Irish medical device giant Covidien has purchased Florida-based New Wave Surgical for more than $100 million.

Daiichi Sankyo lays out road map for Ranbaxy deal with Sun

Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.

Sources: Sun to phase out Ranbaxy brand in U.S.

Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.

TetraLogic bags lymphoma therapy in $13M buyout

Malvern, PA-based TetraLogic is buying up Shape Pharmaceuticals and its Phase II-ready lymphoma gel treatment for $13 million in cash.

Medtronic buys out a distributor as it cozies up to Turkey

Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.

Roche snags diagnostics outfit IQuum in $450M deal

Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire Marlborough, MA-based IQuum for $275 million up front and up to $175 million in milestone-based payments.

Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.

Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug

Ireland's Mallinckrodt has been on a major growth spurt since its spinoff last spring from medical device maker Covidien--and it made another big move Monday in its bid to become a major specialty pharma company.

Sun Pharma hopes to turn fortunes of Ranbaxy around with $3.2B buyout

Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.